leucine rich repeat kinase lrrk 2 inhibitor pipeline insight

DelveInsight’s, “Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor - Pipeline Insight, 2025,” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Understanding

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Overview

Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin, is a large multidomain protein kinase that includes leucine-rich repeats and a GTPase domain. LRRK2 is a 286 kDa complex scaffolding protein containing ankyrin, leucine-rich and WD40 repeats, and a catalytic core with Ras-Of-Complex (ROC) GTPase and serine-threonine kinase activities. Mutations in leucine-rich repeat kinase 2 (LRRK2) are the major genetic cause of autosomal-dominantly inherited Parkinson's disease. Studies found that inhibiting the activity of LRRK2 kinase may benefit patients both with and without Parkinson disease-related mutation. Research and clinical development activities are going on toward the development of pharmacological inhibitors of LRRK2 kinase activity as a therapeutic intervention.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor R&D. The therapies under development are focused on novel approaches for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor.

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Emerging Drugs Chapters

This segment of the Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Emerging Drugs

 

ION859: Ionis Pharmaceuticals

ION859 (formerly IONIS-BIIB7Rx), also known as BIIB094, is an investigational antisense medicine targeting Leucine Rich Repeat Kinase 2 (LRRK2) messenger ribonucleic acid (mRNA). It is designed to prevent the production of LRRK2 protein and is currently under Phase II clinical evaluation for Parkinson’s disease (PD). It is hypothesized that reduction of LRRK2 mRNA and, subsequently, reduced synthesis of LRRK2 protein will ameliorate the toxic effects of gain-of-function mutations as well as the primary pathology in PD patients without the LRRK2 mutation.

 

DNL151: Denali Therapeutics

DNL151 is a potent, selective and brain-penetrant oral small molecule inhibitor of LRRK2. It is in Phase I clinical development for Parkinson's disease. Denali Therapeutics is developing this drug in collaboration with Biogen. Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor DNL201 Phase 1b demonstrated high levels of target and pathway engagement and improvement of lysosomal biomarkers in patients with Parkinson’s disease.

Further product details are provided in the report……..

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor

There are approx. 8+ key companies which are developing the Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor. The companies which have their Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drug candidates in the most advanced stage, i.e. Phase II include, Ionis Pharmaceuticals.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

 

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs.

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Report Insights

• Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs?
• How many Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?